Table 2.
Correlation between HER2/ECD at diagnosis and age, N, M, VI, grade, ER, PR, CA 15.3, and HER2 status
| HER2/ECD <15 | HER2/ECD ≥15 | P value | |
|---|---|---|---|
| Number | 283 | 51 | |
| Age (years) | |||
| <45 | 56 (85 %) | 10 (15 %) | 0.0865 |
| ≥45 to <55 | 103 (90 %) | 11 (10 %) | |
| ≥55 | 124 (81 %) | 30 (19 %) | |
| Lymph node status | |||
| N0 | 162 (86 %) | 26 (14 %) | 0.9449 |
| N+ (pTNM) | 114 (85 %) | 20 (15 %) | |
| No dataa | 7 | 5 | |
| Vascular invasion | |||
| VI− | 239 (83 %) | 49 (17 %) | 0.0458 |
| VI+ | 44 (96 %) | 2 (4 %) | |
| Metastatic status | |||
| M0 | 258 (90 %) | 28 (10 %) | <0.0001 |
| M+ | 25 (52 %) | 23 (48 %) | |
| Grade | |||
| Low grade | 15 (94 %) | 1 (6 %) | 0.5832 |
| Intermediate grade | 103 (84 %) | 19 (16 %) | |
| High grade | 158 (84 %) | 30 (16 %) | |
| No dataa | 7 | 1 | |
| Estrogen receptor status | |||
| ER− | 95 (79 %) | 25 (21 %) | 0.0283 |
| ER+ | 188 (88 %) | 26 (12 %) | |
| Progesterone receptor status | |||
| PR− | 182 (84 %) | 34 (16 %) | 0.8691 |
| PR+ | 101 (86 %) | 17 (14 %) | |
| Tissue HER2 status | |||
| HER2 2+ ISH+ | 27 (90 %) | 3 (10 %) | 0.5946 |
| HER2 3+ | 256 (84 %) | 48 (16 %) | |
| CA 15.3 | |||
| <30 | 252 (91 %) | 26 (9 %) | <0.0001 |
| ≥30 | 31 (55 %) | 25 (45 %) | |
a Patients not operated or no Roche score on breast carcinoma
N lymph node, VI vascular invasion, M metastasis; ER estrogen receptor, PR progesterone receptor